FY2025 · ended Dec 31, 2025 · Revenue $655.35M, +8.3% YoY · Filed Feb 26, 2026
NovoCure Limited (NVCR) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $655.4 million and a net loss of $136.2 million. Free cash flow was -$75.7 million. As of Sep 30, 2026 it held $96.7 million in cash and investments and $60.2 million in total debt.
Revenue (TTM)
$725.39M
+12.9% vs year-ago TTM
Net income (TTM)
$-121.73M
+31.5% vs year-ago TTM
Operating cash flow (TTM)
$-722,000
+97.9% vs year-ago TTM
Free cash flow (TTM)
$-24.61M
+62.2% vs year-ago TTM
EPS (TTM)
$-1.06
+34.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
113.79M
+3.5% vs prior year
Net cash
$36.52M
as of Sep 30, 2026
Operating margin
-17.2%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NVCR (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- St. Helier
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1645113
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M |
| Operating income | -$153.8M | -$170.5M | -$232.9M | -$89.5M | -$44.3M |
| Net income | -$136.2M | -$168.6M | -$207.0M | -$92.5M | -$58.4M |
| Diluted EPS | -$1.22 | -$1.56 | -$1.95 | -$0.88 | -$0.56 |
| Operating cash flow | -$49.0M | -$26.4M | -$73.3M | $30.8M | $82.8M |
| Free cash flow | -$75.7M | -$69.2M | -$100.4M | $9.4M | $58.6M |
| Total assets | $804.3M | $1.2B | $1.1B | $1.2B | $1.1B |
| Total liabilities | $463.9M | $880.6M | $783.6M | $750.5M | $729.0M |
| Stockholders' equity | $340.5M | $360.2M | $362.5M | $441.2M | $410.5M |
| Cash and investments | $93.5M | $163.8M | $240.8M | $115.3M | $208.8M |
| Total debt | $248.4M | $125.2M | $604.5M | $590.1M | $581.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 9, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 23, 2026 | Jul 23, 2026 |
All 1001 NovoCure Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.